Business Context and Reporting Period
This Form 8-K, dated January 28, 2026, is a supplemental disclosure filed by Veeco Instruments Inc. regarding its proposed merger with Axcelis Technologies, Inc. The filing addresses three pending stockholder lawsuits challenging the adequacy of disclosures in the Definitive Proxy Statement. To avoid litigation delays, Veeco voluntarily supplemented the proxy statement with additional details on the transaction background, financial advisor analyses, and executive compensation.
A special meeting of Veeco stockholders to vote on the merger is scheduled for February 6, 2026.
Key Financial Metrics and Transaction Terms
The filing provides specific financial data used in valuation analyses as of June 30, 2025, and forecasts for 2025 and 2026:
- Transaction Structure: All-stock transaction. The initial proposal (August 12, 2025) offered an exchange ratio of 0.340x Axcelis shares for each Veeco share (18% premium to the one-month average), resulting in Veeco stockholders owning 40% of the combined company.
- Veeco Liquidity (June 30, 2025): Cash of approximately $355 million; Debt of approximately $230 million (based on net share settlement of convertible debt).
- Axcelis Liquidity (June 30, 2025): Cash of approximately $581 million; Finance leases of approximately $43 million.
- Combined Company Liquidity (Post-Transaction Fees): Cash of approximately $876 million.
- Veeco Net Income Forecasts: $74 million for 2025E and $95 million for 2026E.
- Valuation Ranges (Implied Equity Value per Share):
- Veeco Standalone: $30.14 to $36.54.
- Veeco in Combined Company: $32.91 to $40.07.
- Axcelis Standalone: $91.91 to $109.93.
- Analyst Price Targets: Veeco ($21.00–$30.00); Axcelis ($81.00–$90.00).
Material Changes and Litigation
The primary material event is the filing of three stockholder complaints in New York Supreme Court challenging the merger disclosures:
- Turner v. Veeco Instruments Inc. et al. (Filed Jan 14, 2026): Alleges negligence and negligent misrepresentation.
- Clark v. Veeco Instruments Inc. et al. (Filed Jan 15, 2026): Similar allegations against Veeco, its board, and Axcelis.
- Garfield v. Bayless et al. (Filed Jan 20, 2026): Alleges failure to disclose and breach of fiduciary duties. A motion for a preliminary injunction to stop the stockholder vote was filed on January 25, 2026.
Veeco and Axcelis deny all allegations and believe the claims are without merit. However, the supplemental disclosures were made solely to eliminate litigation burdens and avoid potential delays to the merger.
Guidance, Outlook, and Management Commentary
Management Commentary on Governance and Process:
- Board Independence: Thomas St. Dennis serves as a director on both boards but recused himself from all discussions regarding the transaction and did not receive confidential information.
- Strategic Planning: A Veeco Strategic Planning Committee was formed in May 2024 to evaluate alternatives. It was not empowered to approve transactions but facilitated the process.
- Negotiation History: Veeco's counterproposal (August 19, 2025) sought an increased exchange ratio of 0.375x, equal board representation, and Dr. Miller as Chairperson. The committee remained open to Mr. St. Dennis as Chairperson given his familiarity with both companies.
- Employment Arrangements: No employment agreements were negotiated or entered into prior to the Merger Agreement execution. No executive officers or directors have entered into agreements with Axcelis for post-closing employment as of the filing date.
Risks and Contingencies:
- Regulatory and Approval Risks: The transaction is subject to stockholder approval and regulatory conditions.
- Integration Risks: Potential failure to realize synergies, cost savings, or growth; disruption to operations; and unanticipated integration costs.
- Market Risks: Dependence on semiconductor industry demand, export control licenses (specifically for China), and competition.
- 280G Mitigation: Veeco may take actions to mitigate excise taxes on executives, potentially accelerating vesting of equity awards, though no specific actions were approved as of the filing date.
Investor Verification Checklist
- Verify the status of the Garfield Action preliminary injunction motion filed on January 25, 2026, and its potential impact on the February 6, 2026, special meeting.
- Confirm the final exchange ratio and whether the 0.340x proposal or the 0.375x counterproposal was the basis for the final agreement.
- Review the Definitive Proxy Statement (Form S-4) in its entirety, as this 8-K only provides supplemental disclosures.
- Assess the financial advisor fees: UBS is estimated to receive approximately $28.5 million from Veeco, with $3.0 million already payable and the remainder contingent on closing.
- Monitor executive compensation changes, specifically regarding the vesting of RSUs and PSUs for executives like Dr. William J. Miller and John P. Kiernan, and any potential 280G mitigation actions.
- Check for updates on regulatory approvals and export control licenses, particularly regarding sales to China, which are cited as a material risk.